SG165364A1 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
SG165364A1
SG165364A1 SG201006580-3A SG2010065803A SG165364A1 SG 165364 A1 SG165364 A1 SG 165364A1 SG 2010065803 A SG2010065803 A SG 2010065803A SG 165364 A1 SG165364 A1 SG 165364A1
Authority
SG
Singapore
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
SG201006580-3A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG165364A1 publication Critical patent/SG165364A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG201006580-3A 2005-09-09 2006-09-07 Treatment of autoimmune diseases SG165364A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
SG165364A1 true SG165364A1 (en) 2010-10-28

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006580-3A SG165364A1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Country Status (29)

Country Link
US (1) US20080200438A1 (da)
EP (2) EP1926483B1 (da)
JP (4) JP5244598B2 (da)
KR (3) KR20140117704A (da)
CN (1) CN101257899B (da)
AT (1) ATE489948T1 (da)
AU (2) AU2006289100B2 (da)
BR (1) BRPI0615906A2 (da)
CA (2) CA2820510A1 (da)
CY (1) CY1111285T1 (da)
DE (1) DE602006018629D1 (da)
DK (2) DK1926483T3 (da)
ES (2) ES2357426T3 (da)
HK (1) HK1149906A1 (da)
IL (2) IL189665A (da)
JO (1) JO2655B1 (da)
MA (1) MA29787B1 (da)
MX (1) MX2008003170A (da)
NO (1) NO20081727L (da)
NZ (2) NZ566137A (da)
PL (2) PL2295049T3 (da)
PT (2) PT1926483E (da)
RU (2) RU2424795C2 (da)
SG (1) SG165364A1 (da)
SI (2) SI1926483T1 (da)
TN (1) TNSN08103A1 (da)
TW (2) TWI376223B (da)
WO (1) WO2007028821A2 (da)
ZA (1) ZA200801694B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SI2058317T1 (sl) * 2006-08-08 2014-01-31 Kyorin Pharmaceutical Co., Ltd. Derivat estra aminofosforjeve kisline in S1P receptorski modulator, ki ga vsebuje kot učinkovino
AU2007282556B2 (en) * 2006-08-08 2012-03-08 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
CN102123735A (zh) * 2008-05-20 2011-07-13 杏林制药株式会社 诱导缓解维持剂
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
CA2795394A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Treatment of autoimmune diseases
MX2012012925A (es) * 2010-05-06 2012-12-17 Novartis Ag Regimen de dosificacion de derivados de sulfuro de diarilo.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
IL131608A (en) * 1997-02-27 2003-02-12 Welfide Corp Pharmaceutical composition and kit containing the same
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
DK1431284T3 (da) * 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
MXPA05003080A (es) * 2002-09-19 2005-06-15 Kyorin Seiyaku Kk Derivado de amino alcohol, sales de los mismos y agentes inmunosupresores.
EP2251007A3 (en) * 2002-09-24 2011-03-23 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
EP1545472B1 (en) * 2002-09-28 2010-12-08 McNeil-PPC, Inc. Modified release dosage forms with two cores and an opening
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
KR101367574B1 (ko) * 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 S1p 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
DE602004024213D1 (en) * 2003-08-28 2009-12-31 Novartis Ag Aminopropanolderivate
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト S1p受容体アゴニストの投与レジメン
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MA29787B1 (fr) 2008-09-01
JP2017019854A (ja) 2017-01-26
ES2529724T3 (es) 2015-02-25
RU2011111117A (ru) 2012-09-27
AU2006289100B2 (en) 2010-07-22
DK1926483T3 (da) 2011-03-14
AU2010224355B2 (en) 2012-03-29
IL233328A0 (en) 2014-08-31
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
RU2424795C2 (ru) 2011-07-27
NO20081727L (no) 2008-06-06
JP2013010802A (ja) 2013-01-17
KR20140019033A (ko) 2014-02-13
RU2493840C2 (ru) 2013-09-27
CA2620554A1 (en) 2007-03-15
CN101257899A (zh) 2008-09-03
IL189665A (en) 2014-07-31
KR20140117704A (ko) 2014-10-07
JP5244598B2 (ja) 2013-07-24
EP1926483A2 (en) 2008-06-04
ZA200801694B (en) 2009-09-30
PT2295049E (pt) 2015-03-02
CN101257899B (zh) 2012-10-03
NZ588372A (en) 2012-03-30
RU2008113187A (ru) 2009-10-20
DE602006018629D1 (de) 2011-01-13
PL1926483T3 (pl) 2011-05-31
DK2295049T3 (da) 2015-02-23
JO2655B1 (en) 2012-06-17
TWI372620B (en) 2012-09-21
ATE489948T1 (de) 2010-12-15
JP2009507810A (ja) 2009-02-26
JP2015025002A (ja) 2015-02-05
HK1149906A1 (en) 2011-10-21
PT1926483E (pt) 2011-03-03
TWI376223B (en) 2012-11-11
SI2295049T1 (sl) 2015-03-31
IL189665A0 (en) 2008-06-05
NZ566137A (en) 2011-05-27
WO2007028821A2 (en) 2007-03-15
CA2820510A1 (en) 2007-03-15
WO2007028821A3 (en) 2007-05-03
JP6077265B2 (ja) 2017-02-08
CA2620554C (en) 2013-12-17
MX2008003170A (es) 2008-03-18
TW200803829A (en) 2008-01-16
AU2010224355A1 (en) 2010-10-14
ES2357426T3 (es) 2011-04-26
KR20080046231A (ko) 2008-05-26
KR101476451B1 (ko) 2014-12-24
PL2295049T3 (pl) 2015-04-30
EP2295049A1 (en) 2011-03-16
EP1926483B1 (en) 2010-12-01
TW201034659A (en) 2010-10-01
CY1111285T1 (el) 2015-08-05
TNSN08103A1 (en) 2009-07-14
BRPI0615906A2 (pt) 2011-05-31
EP2295049B1 (en) 2014-11-26
AU2006289100A1 (en) 2007-03-15
SI1926483T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
SG165364A1 (en) Treatment of autoimmune diseases
TW200509892A (en) Novel aminobenzophenone compounds
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2006023651A3 (en) Extended treatment of multiple sclerosis
GB2430935A (en) Tetrapeptide analogs
BRPI0413449A (pt) compostos de quinoxalina
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
NO20072092L (no) Sulfonamidforbindelser
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MXPA06004308A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables.
PT1744736E (pt) Método de tratamento de distúrbios do olho seco e uveíte
MXPA06002315A (es) Abridores de canal erg para el tratamiento de arritmias cardiacas.
UA84302C2 (ru) Изопентилкарбоксанилиды и способ борьбы с нежелательными микроорганизмами
TW200714284A (en) Novel method
WO2004056762A3 (en) Novel aminobenzophenone compounds
TW200628453A (en) Triazole substituted aminobenzophenone compounds
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων